Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma
Jacqueline Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory L. Beatty
Jacqueline Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory L. Beatty
View: Text | PDF
Research Article Immunology Inflammation Oncology

TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDAC) shows profound resistance to immunotherapy due to its immunosuppressive tumor microenvironment. Here, we studied the relationship between T cell infiltration and innate immune signaling in PDAC, identifying TLR2 as a key regulator of T cell exclusion. TLR2 expression correlated with T cell infiltration in both human and mouse PDAC tumors. Using genetic KO models and adoptive T cell transfer experiments, we found that TLR2 expression in both T cells and non–T cells contributes to T cell exclusion in PDAC. Notably, successful infiltration of adoptively transferred tumor-specific T cells required TLR2 deletion in both the transferred cells and the recipient host. The therapeutic implications of these findings are demonstrated through both genetic deletion and pharmacological inhibition of TLR2 using AAV-mediated and antibody-based approaches in murine models, resulting in decreased tumor growth and extended survival. Collectively, these findings identify TLR2 as a key modulator of T cell trafficking and immune suppression within the PDAC microenvironment, suggesting its potential as a therapeutic target for improving treatment outcomes.

Authors

Jacqueline Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory L. Beatty

×

Figure 1

The immune microenvironment in PDAC determines adoptive T cell infiltration and efficacy.

Options: View larger image (or click on image) Download as PowerPoint
The immune microenvironment in PDAC determines adoptive T cell infiltrat...
(A) In vitro xcelligence T cellhi (2838c3) and T celllo (PDA.69) tumor cell survival after mesothelin or mock CAR T cells treatment (9:1 E:T). (B) Study design of C–K. T cellhi or T celllo cells (1 × 106) were implanted s.c. into WT mice (n = 5–8/group) on day –14. Mice received cyclophosphamide (120 mg/kg dose, i.p.) on day –1, followed by meso CAR-T cell infusions (5 × 106 to 8 × 106 cells/mouse, i.v.) on days 0 and 7. Data shown in C–K are representative of n = 2 experimental replicates. (C) Meso-CAR T cell trafficking in Cy versus Cy + CAR T cell–treated T cellhi and T celllo tumors (Mann-Whitney U test performed). (D) Tumor growth curve (2-way ANOVA performed), (E) tumor volumes at day 24 (Mann-Whitney U test performed), and (F) overall survival curve (Mantel-Cox test performed) of mice bearing T cellhi tumors treated with Cy or Cy + meso-CAR T cells. (G) Tumor growth curve (2-way ANOVA performed), (H) tumor volumes at day 18 (Mann-Whitney U test performed), and (I) overall survival curve (Mantel-Cox test performed) of mice bearing T celllo tumors treated with Cy or Cy + meso-CAR T cells. (J) Representative images of tumors stained for CD3 (pink), Ki67 (yellow) ,and CK19 (blue). Scale bar: 100 μm. (K) Analysis of T cell Density (CD3+) from J (Mann-Whitney U test performed).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts